The US Securities and Exchange Commission (SEC) has heard the plea of small biotechs that are overwhelmed by Sarbanes-Oxley (SOX) financial accounting compliance costs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Web links
Rights and permissions
About this article
Cite this article
Lawrence, S. Sarbanes-Oxley rules to be relaxed?. Nat Biotechnol 24, 731–732 (2006). https://doi.org/10.1038/nbt0706-731
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0706-731
This article is cited by
-
Public biotech 2006—the numbers
Nature Biotechnology (2007)
-
Profile: Elliot Entis
Nature Biotechnology (2006)
-
News In Brief
Nature Biotechnology (2006)
